The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel

References

• Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364: 937–52
   Google Scholar
• Grundy SM, Cleeman JI, Bairey Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227–39
   Google Scholar
• Williams B, Poulter NR, Brown MJ, et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society Guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328: 634–40
   Google Scholar
• Department of Health. National Service Framework for Coronary Heart Disease. London: DoH, 2000
   Google Scholar
• Joint British recommendations on prevention of coronary heart disease in clinical practice: British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart 1998;80(Suppl 2):S1–29
   PubMedGoogle Scholar
• Scottish Intercollegiate Guidelines Network. Secondary prevention of CHD following myocardial infarction. Edinburgh: SIGN, 2000
   Google Scholar
• Scottish Intercollegiate Guidelines Network. Lipids and the primary prevention of coronary heart disease. Edinburgh: SIGN, 1999
   Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1–10
   Google Scholar
• GMS Contract. Summary of Quality Indicators. Available from www.bma.org.uk/ap.nsf/content/QualityOutcomes [Last accessed 15 April 2005]
   Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–504
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:23–30
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–30
   Google Scholar
• Sever PS, Dahlof B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo–Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multi-centre randomised controlled trial. Lancet 2003;361:1149–58
   Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998–3007
   Google Scholar
• British Heart Foundation. Coronary Heart disease Statistics: Factsheet. 2004. Available from http://www.bhf.org.uk/professionals/index.asp?SecID=15&secondlevel=519 [Last accessed 15 April 2005]
   Google Scholar
• British Heart Foundation. BHF Health Professionals. Coronary Heart Disease Statistics 2004. Available from http://www.bhf.org.uk/professionals/index.asp?SecID=15&secondlevel=519 [Last accessed 15 April 2005]
   Google Scholar
• de Lusignan S, Dzregah B, Hague N, et al. Cholesterol management in patients with IHD: an audit-based appraisal of progress towards clinical targets in primary care. Br J Cardiol 2003;10:223–8
   Google Scholar
• Brady AJ, Oliver MA, Pittard JB. Secondary prevention in 24 431 patients with coronary heart disease: Survey in primary care. BMJ 2001;322: 1463
   Google Scholar
• EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554–72
   PubMed Web of Science ®Google Scholar
• Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498–511
   PubMed Web of Science ®Google Scholar
• Stein EA. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J 2001;3(Suppl E):E11–6
   Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681–90
   PubMed Web of Science ®Google Scholar
• Wooltorton E. Rosuvastatin (Crestor) and rhabdomyolysis. CMAJ 2004;171:129
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19:155–68
   PubMed Web of Science ®Google Scholar
• Davis Jr HR, Zhu L, Hoos LM, et al. Niemann–Pick C1 Like 1 (NCP1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004;279:33586–92
   PubMed Web of Science ®Google Scholar
• Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolaemia. J Am Coll Cardiol 2002;40:2125–34
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A, et al. Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolaemia: a prospective, randomized, double-blind trial. Circulation 2003;107: 2409–15
   Google Scholar
• Melani L, Mills R, Hassman D, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe co-administered with pravastatin in patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Eur Heart J 2003;24:717–28
   Google Scholar
• Kerzner B, Corbelli J, Sharp S, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe co-administered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418–24
   Google Scholar
• Feldman T, Koren M, Insull W, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein goals. Am J Cardiol 2004;93:1481–6
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Yang B, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004;20:1185–95
   PubMed Web of Science ®Google Scholar
• Gagne C, Bays HE, Weiss SR, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084–91
   Google Scholar
• Pearson T, Denke M, McBride P, et al. Ezetimibe added to statin therapy reduces LDL-C and improves goal attainment in patients with hypercholesterolemia. Program and abstracts from the American College of Cardiology 53rd Annual Scientific Session; March 7–10, 2004; New Orleans, Louisiana. Late Breaking Clinical Trials III
   Google Scholar
• Ballantyne CM, Lipka LJ, Sager PT, et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolemia. Int J Clin Pract 2004;58:653–8
   PubMed Web of Science ®Google Scholar
• Medicines Control Agency. Adverse drug reactions online information tracking. Ezetimibe. Available from medicines.mhra.gov.uk [Last accessed 15 April 2005]
   Google Scholar
• Ezetimibe (Ezetrol) Summary of Product Characteristics. Available from http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=12091 [Last accessed 15 April 2005]
   Google Scholar
• Kosoglou T, Statkevich P, Fruchart JC. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004;20:1197–207
   Google Scholar
• Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005;26:897–905 [doi:10.1093/ eurheartj/ehi231]
   Google Scholar
• Chiou P, Xydakis AM, Guyton JR, et al. Efficacy and tolerability of ezetimibe add-on therapy in bile acid sequestrant/niacinbased regimes. Arterioscler Thromb Vasc Biol 2004;24:132 [Abstract 467]
   Google Scholar
• Xydakis AM, Guyton JR, Chiou P, et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile-acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004;94:795–7
   PubMed Web of Science ®Google Scholar
• Reyderman L, Kosoglou T, Statkevich P, et al. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Int J Clin Pharmacol Ther 2004;42:512–8
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707–14
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8–15
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Blazing MA, King TR, et al. Efficacy and Safety of Ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487–94
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu M, Schoenhagen P, et al. for the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. N Engl J Med 2005;352:29–38
   Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-Reactive Protein Levels and Outcomes after Statin Therapy. N Engl J Med 2005;352:20–8
   Google Scholar
• Lipka L, Sager P, Capece R, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Poster. European Atherosclerosis Society. Spain: Seville, April 2004
   Google Scholar
• Goldberg AC, Sapre A, Liu J, et al. Ezetimibe Study Group. Efficacy and Safety of Ezetimibe Coadministered with Simvastatin in Patients with Primary Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Trial. Mayo Clin Proc 2004;79:620–9
   Google Scholar
• Sager PT, Melani L, Lipka L, et al. Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414–18
   Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364: 685–96
   Google Scholar
• Gagne C, Gaudet D, Bruckert E. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469–75
   Google Scholar
• Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048–58
   PubMed Web of Science ®Google Scholar
• Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005;50:171–80
   Google Scholar
• British Heart Foundation. Cholesterol screening in children and adolescents. Available from www.bhf.org.uk [Last accessed 15 April 2005]
   Google Scholar
• Daskalopoulou SS, Daskalopoulos ME, Liapis CD, et al. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Medicinal Chem 2005;12:443–52
   PubMed Web of Science ®Google Scholar
• von Lintig FC, Lee D, Patel P, et al. Effectiveness of ezetimibe on hyperlipidaemia in HIV-1-infected patients. Antiviral Therapy 2004;9:L48 [Abstract 83]
   Google Scholar
• Wierzbicki AS, Doherty E, Lumb PJ, et al. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 2005;21:333–8
   PubMed Web of Science ®Google Scholar